Intravenous Infusions Plc announced unaudited earnings results for the half year ended June 30, 2017. For the period, the company reported revenue was GHS 6,316,853 against GHS 4,781,354 a year ago. Proft before finance cost and tax was GHS 1,522,056 against GHS 817,815 a year ago. Proft before tax was GHS 1,110,934 against GHS 596,981 a year ago. Proft for the year was GHS 902,634 against GHS 485,047 a year ago. Net cash used operating activities was GHS 546,186 against GHS 4,670,417 a year ago. Purchases of equipment was GHS 253,858 against GHS 361,382 a year ago.

The company provides guidance for the second half of 2017. The outlook for the second half of the year remains positive. Revenue is projected to grow stronger than what has been recorded for the first half of the year, as enter the rainy season of July to September. Management is taking proactive measures to ensure that adequate raw materials are available for production during the second half of 2017. Production as at the beginning of July is now on a one-half shift system, resulting in an increase in output quantities by 50%. Production is expected to move unto a complete two-shift system by September 2017.